Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Theophylline Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 10/20 | 0.74 |
| ▸ | PDE4B known ✓ | Q07343 | 10/20 | 0.74 |
| ▸ | PDE4C known ✓ | Q08493 | 10/20 | 0.74 |
| ▸ | PDE4D known ✓ | Q08499 | 10/20 | 0.74 |
| ▸ | ADORA2A known ✓ | P29274 | 8/20 | 0.74 |
| ▸ | ADORA2B known ✓ | P29275 | 8/20 | 0.74 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 0.74 |
| ▸ | ADORA1 known ✓ | P30542 | 2/20 | 0.74 |
| ▸ | PDE3B known ✓ | Q13370 | 1/20 | 0.55 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.86 |
| ▸ | LMNA | P02545 | 1/20 | 0.86 |
| ▸ | MAPT | P10636 | 1/20 | 0.86 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.77 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.74 |
| ▸ | ALPL | P05186 | 1/20 | 0.74 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.74 |
| ▸ | CFTR | P13569 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Theophylline Anhydrous SCHEMBL393183 | 0.92 | CYP1A2 (1.00) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL5037 | 0.92 | CYP1A2 (1.00) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL28294581 | 0.92 | ATAD2 (0.84) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL1321168 | 0.92 | CYP1A2 (1.00) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL5181434 | 0.92 | CYP1A2 (1.00) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL7546366 | 0.91 | CYP1A2 (0.97) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL11187438 | 0.91 | CYP1A2 (0.97) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL1022085 | 0.91 | CYP1A2 (0.97) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL19987964 | 0.91 | CYP1A2 (0.97) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL9792548 | 0.91 | CYP1A2 (0.97) | CYP1A2LMNAMAPTATAD2PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-206314513-U | Organic base material structure capable of rapidly dissolving out precipitated substance | 兴沅工业股份有限公司 | 2017-07-11 | — | — | CN | claimed |
| CN-101629110-B | Low-dose high-level transparent microemulsified nanometer particle size fuel taking theamin modified sugar as heat value agent | ZHAN XIAOLING | 2013-06-26 | — | — | CN | claimed |
| CN-101629110-A | Low-dose high-level transparent microemulsified nanometer particle size fuel taking theamin modified sugar as heat value agent | XIAOLING ZHAN | 2010-01-20 | — | — | CN | claimed |
| EP-0270305-B1 | SPHEROIDS | Euroceltique S.A. (LU) | 1993-01-20 | — | — | EP | claimed |
| US-4844910-A | CONTROLLED RELEASE OF THEOPHYLLINE DERIVATIVES | EUROCELTIQUE, S.A. (LU) | 1989-07-04 | — | — | US | claimed |
| EP-0270305-A2 | Spheroids | Euroceltique S.A. (LU) | 1988-06-08 | — | — | EP | claimed |
| US-4014334-A | Laminated osmotic system for dispensing beneficial agent | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
| US-4008719-A | Osmotic system having laminar arrangement for programming delivery of active agent | ALZA CORPORATION (US) | 1977-02-22 | — | — | US | claimed |
| CN-122080002-A | Phthalazinone compound and preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12607625-B2 | Method for eliminating interference of theophylline in immunoassay and immunoassay kit | SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. (CN) | 2026-04-21 | — | — | US | disclosed |
| CN-112805564-B | Method for eliminating theophylline interference in immunoassay and immunoassay kit | 武汉全景生物技术有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20220018831-A1 | METHOD FOR ELIMINATING INTERFERENCE OF THEOPHYLLINE IN IMMUNOASSAY AND IMMUNOASSAY KIT | SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| CN-112807283-A | Novel oral pellet drug delivery system for gastrointestinal tract | 江苏集萃新型药物制剂技术研究所有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-112805564-A | Method for eliminating theophylline interference in immunoassay and immunoassay kit | 深圳迈瑞生物医疗电子股份有限公司 | 2021-05-14 | — | — | CN | disclosed |
| US-4160020-A | CELLULOSE ESTERS, CELLULOSE ETHERS | ALZA CORPORATION (US) | 1979-07-03 | — | — | US | disclosed |
| US-4116241-A | FOR CONTROLLED ORAL ADMINISTRATION OF DRUG | ALZA CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-4077407-A | POLYSACCHARIDES | ALZA CORPORATION (US) | 1978-03-07 | — | — | US | disclosed |
| US-4058122-A | Osmotic system with laminated wall formed of different materials | ALZA CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
| US-4014334-A | Laminated osmotic system for dispensing beneficial agent | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-4008719-A | Osmotic system having laminar arrangement for programming delivery of active agent | ALZA CORPORATION (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12607625-B2 | Method for eliminating interference of theophylline in immunoassay and immunoassay kit | TPMT, TYMP, ADA | PDE4A 129/4885PDE4B 152/4885PDE4C 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.